Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinmailong Injection for Chemotherapy-Induced Cardiotoxicity in Breast Cancer
NCT03785704Phase 2Unknown
- Sponsor
- Peking Union Medical College
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xinmailong in chemotherapy-induced cardiotoxicity (CIC), sponsored by Peking Union Medical College. Status: unknown.
02
Drugs
xinmailong
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)
Beyond the preview
Go deeper on NCT03785704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785704.